{
    "clinical_study": {
        "@rank": "73678", 
        "arm_group": [
            {
                "arm_group_label": "MT-9938 2.5\u03bcg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "MT-9938  5\u03bcg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "MT-9938  10\u03bcg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to investigate the efficacy of MT-9938 compared with placebo\n      after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore\n      the effect of a reduction in itching intensity on health-related Quality of Life(QoL)\n      domains, especially those which recent research suggests have a positive correlation with\n      overall survival for this patient group.  The study will consist of the following phases:\n      Screening (1 to 2 weeks), Run in (1 week), double-blind Treatment (8 weeks), Washout (1\n      week) culminating in a Follow-up Visit (1 week after the last dose)."
        }, 
        "brief_title": "Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Uremic Pruritus", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Pruritus"
            ]
        }, 
        "detailed_description": {
            "textblock": "MT-9938 is a potent and selective agonist for the kappa -opioid receptor and a novel\n      derivative of the opioid receptor antagonist, naltrexone. Although MT-9938 is not designated\n      a Schedule-controlled substance in Japan and Europe, MT-9938 is currently a Schedule II\n      substance under the Controlled Substance Act in the United States as a derivative of\n      noroxymorphone based on the chemical structure. DOPPS has reported 70% of patients having\n      some degree of pruritus, with 42-45% moderately-to-extremely being bothered by itchiness.\n      For this subset of hemodialysis patients, the intensity of pruritus is highly correlated\n      with multiple measures of QoL."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  On stable hemodialysis for at least 3 months\n\n          -  Has stable functioning arteriovenous fistula, graft or other venous access\n\n          -  Has continued (uncontrolled) uremic pruritus despite standard of care in the\n             institution\n\n          -  Has severe pruritus, as determined by a qualifying score of \u22653 on the Itch Severity\n             Score Scale (0 to 4) either day or night during the week prior to Screening Visit\n\n          -  Has no known drug addiction to any prescription, nonprescription, herbal or natural\n             drugs, and successfully passes a drug screen test\n\n          -  Women and men whose partners are of childbearing potential agree to practice the\n             medically acceptable methods of birth control and agree to continue with the regimen\n             throughout the duration of the study\n\n          -  Capable of understanding and responding to the subject questionnaires, understands\n             the purpose and risks of the study, and has given written informed consent\n\n          -  Has rated his/her NRS score each day for at least 5 days out of the 7 days of  the\n             Run-in Phase\n\n          -  Has severe pruritus, as determined by qualifying mean worst NRS score in a day of \u22655\n             (on 11 point NRS) at the end of the 1-week Run-in Phase\n\n        Exclusion Criteria:\n\n          -  Current, clinically significant medical comorbidities\n\n          -  Abnormal liver dysfunction\n\n          -  Pruritus attributed mainly to any disease unrelated to kidney disease\n\n          -  Calcium x phosphorus product >80 mg2/dL2 or hemoglobin <7 g/dL or parathyroid hormone\n             levels >1000 pg/mL at Screening\n\n          -  Received ultraviolet B treatment within 30 days prior to Screening\n\n          -  Started or changed psychotropic medication within 14 days prior to Screening\n\n          -  Is receiving opioid antagonists or opioid agonists within 7 days prior to Screening\n             and not willing to abstain from these medications during the study.\n\n          -  Started or changed medications, creams or emollients including over-the-counter oil\n             bath treatment for relief of pruritus within 7 days prior to Screening\n\n          -  Has known hypersensitivity to opioids or the study drug ingredients\n\n          -  Is currently participating in an investigational drug or device clinical study or was\n             participating in such a study within 30 days prior to the start of Screening\n\n          -  Female subject who is known to be pregnant or nursing\n\n          -  Is considered not suitable for inclusion in the study in the opinion of Investigator\n\n          -  Has current suicidal ideation with some intent to act or with specific plan and\n             intent or had suicidal behavior at any time in subject's life"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660243", 
            "org_study_id": "MT-9938-A01"
        }, 
        "intervention": [
            {
                "arm_group_label": "MT-9938 2.5\u03bcg", 
                "description": "2.5 \u03bcg (2capsules) once daily for 8 weeks", 
                "intervention_name": "Nalfurafine hydrochloride  2.5\u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-9938  5\u03bcg", 
                "description": "5 \u03bcg (2capsules) once daily for 8 weeks", 
                "intervention_name": "Nalfurafine hydrochloride   5\u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-9938  10\u03bcg", 
                "description": "10 \u03bcg (2capsules) once daily for 8 weeks", 
                "intervention_name": "Nalfurafine hydrochloride  10\u03bcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo (2capsules) once daily for 8 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pruritus", 
            "Renal dialysis", 
            "Receptors, Opioid, kappa", 
            "Sleep Disorders", 
            "Quality of Life"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosedale", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in Worst-itching 11-point Numerical Rating Scale (NRS)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 week"
            }, 
            {
                "measure": "Change from baseline in Worst-itching Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }, 
            {
                "measure": "Change from baseline in Itch Severity Score", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }, 
            {
                "measure": "Change from baseline in Sleep quality assessment", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }, 
            {
                "measure": "Change from baseline in Excoriation", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }, 
            {
                "measure": "Change from baseline in QoL assessment", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }, 
            {
                "measure": "Change from baseline in Treatment satisfaction (Patient's Global Impression of Change )", 
                "safety_issue": "No", 
                "time_frame": "2 weeks, 4 weeks and 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660243"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}